Jessica Merrill

Jessica Merrill

Senior Editor

Brooklyn, NY

Jessica is a senior editor, contributing most frequently to daily pharmaceutical coverage in Scrip and Pink Sheet. With a lengthy career covering the pharmaceutical sector, she specializes primarily in business and commercial news, launch strategy, M&A and market access issues.

Latest from Jessica Merrill

Leo Pharma Picks Up Momentum As Growth Plan Progresses

CEO Christophe Bourdon talked to Scrip about the company’s revitalization as revenue grew 10% in the third quarter.

The Scrip 100: Changes At The Top Of The Leaderboard

Pfizer continued its reign as the Scrip 100 leader for a third year, while Lilly and Novo climbed higher.

Novartis Gains Next-Generation Gene Therapy Tech With Kate Acquisition

The Swiss pharma acquired Kate Therapeutics for up to $1.1bn, gaining preclinical gene therapies for neuromuscular conditions and novel platform technology.

Pfizer Picks Boshoff To Head R&D, A Smooth Transition In An Uncertain Time

Chris Boshoff has been with Pfizer more than 10 years and has led oncology R&D and the integration of Seagen. He will succeed Mikael Dolsten, who will depart after leading R&D for nearly 15 years.

Merck & Co.’s Subcutaneous Keytruda Matches I.V.

The new formulation is expected to play a role in helping Merck maintain its multibillion-dollar cancer franchise after Keytruda loses exclusivity in 2028.

Regenxbio Sets Sights On 2026 Filing For DMD Gene Therapy

The company has reached agreement with the US FDA on a pivotal trial for RGX-202 through an accelerated pathway.